Industry News

Let's see what's new in the market

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

Emergent BioSolutions Inc. is carrying out the Phase 3 clinical trial that is evaluating plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is evaluating the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.

3M: Harvesting proteins to find a vaccine for COVID-19

As scientists rush to develop COVID-19 vaccines, safety is a top concern for people around the world. Researchers are quick to point out they are not skipping any steps to ensure the safety and effectiveness of new vaccines. Several factors contribute to the speed of development: the sheer volume of dedicated resources, the ability to combine steps and newer ways of developing vaccines and therapeutics. 3M is helping in the fight against the pandemic from multiple angles, including working alongside biopharmaceutical companies as they develop and manufacture protein-based vaccines and therapeutics. Indeed, the most promising therapeutics right now are protein-based drugs, where the drug is a protein. Pharmaceutical companies make protein drugs by genetically engineering a cell – usually a mammalian cell – to make the protein. The engineered cells are grown in a culture for 48 or 72 hours. After that time, they will have a fluid that contains the protein drug the cells have made, but it also contains the cells, debris from broken cells, and all sorts of other proteins that have been produced by the cells. Once they harvest the fluid, they have to isolate the drug protein from cell fragments, from other proteins the cells have made, and also from DNA and other contaminants. It’s typically a 15- to 20-step process to isolate the drug protein in a pure form.

Dr Reddy’s launches succinylcholine chloride injection

Dr Reddy’s Laboratories announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the US Food and Drug Administration (USFDA).

The Quelicin® brand and generic market had US sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health. Dr Reddy’s Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), is available in multi-dose vials.

Recipients of 3M’s COVID-19 R&D grants announced

As the pandemic brought the world to a halt in 2020, 3M announced in April an initiative to provide $5 million in grants for COVID-19 research and development at leading education institutions in the United States and around the world.

Through a competitive vetting process of multiple universities that are working to develop treatments for COVID-19, ten institutions have been chosen, with funds disbursed to nine so far. “We provided grants to selected universities, in all the regions of the world, based on their reputation and commitment to fight this pandemic,” said Dr. Oyebode Taiwo, corporate medical director at 3M. “These grants will be used in the areas of screening, testing, diagnostics, treatment and prevention of COVID-19.” The projects funded span four continents and include work in Korea to develop an anti-viral treatment, a study in Dublin of existing drugs for their effect on the virus and for research in Israel that seeks a vaccine to prevent the virus from latching on to receptors in the lungs.

Bruker Introduces Vutara™ VXL Best-in-Class Super-Resolution Microscope and Spatial Biology Analysis Capabilities

Accessible 3D Single-Molecule Localization Microscopy for Studying Subcellular Organelles and Spatial Multiomics. The new system opens an affordable and easy-to-use path for both core facilities and individual investigators to enter the world of super-resolution imaging by incorporating Bruker’s industry-leading single-molecule localization (SML) technology in a streamlined system with compact footprint. Vutara VXL serves as a biological microscopy workstation for research on DNA, RNA and proteins, from macromolecular complexes and super-structures, to chromatin structure and chromosomal substructures, to studying functional relationships in genomes and in various subcellular organelles. This novel system also supports advanced spatial biology research in extracellular matrix structures, extracellular vesicles (EV), virology, neuroscience, and live-cell imaging.